A candidate dual vaccine against influenza and noroviruses

Vaccine

Volumn 29, Issue 44, 2011, Pages 7670-7677

  Xia, Ming ^a   Tan, Ming ^a,b   Wei, Chao ^a   Zhong, Weiming ^a   Wang, Leyi ^a   McNeal, Monica ^a,b   Jiang, Xi ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dual vaccine; Influenza; M2e; Norovirus; P particle; Platform

Indexed keywords

AMINO ACID; CHIMERIC PROTEIN; INFLUENZA VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; PROTEIN M2;

ARTICLE; BLOOD GROUP; CONTROLLED STUDY; ELEMENTARY PARTICLE; FEMALE; HISTOLOGY; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RNA VIRUS; SURVIVAL RATE; WILD TYPE;

ANIMALS; CAPSID PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; NOROVIRUS; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, COMBINED; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 80053580021     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.139     Document Type: Article

References (37)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
2. Grandea A.G., Olsen O.A., Cox T.C., Renshaw M., Hammond P.W., Chan-Hui P.Y., et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 2010, 107:12658-12663.
3. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008, 80:168-177.
4. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
5. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londono-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
6. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
7. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
8. Pinto L.H., Lamb R.A. Controlling influenza virus replication by inhibiting its proton channel. Mol Biosyst 2007, 3:18-23.
9. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65:5491-5498.
10. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7:171-177.
11. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102.
12. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
13. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283:11382-11387.
14. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
15. Tan M., Huang P., Xia M., Fang P.A., Zhong W., McNeal M., et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011, 85:753-764.
16. Tan M., Jiang X. Norovirus-host interaction: implications for disease control and prevention. Expert Rev Mol Med 2007, 9:1-22.
17. Tan M., Farkas T., Jiang X. Molecular Pathogenesis of Human Norovirus. RNA virus: host gene responses to infection 2009, 575-600. World Scientific, Singapore. 1st ed. D.C. Yang (Ed.).
18. Tan M., Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol 2005, 13:285-293.
19. Tan M., Jiang X. Norovirus gastroenteritis, increased understanding and future antiviral options. Curr Opin Investig Drugs 2008, 9:146-151.
20. Tan M., Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog 2010, 6:e1000983.
21. Tan M., Jiang X. Virus-host interaction and celluar receptors of caliciviruses. Caliciruses 2010, 111-130. Caister Academic Press, Norwich. G. Hansman, X. Jiang, K. Green (Eds.).
22. Prasad B.V., Hardy M.E., Dokland T., Bella J., Rossmann M.G., Estes M.K. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999, 286:287-290.
23. Tan M., Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005, 79:14017-14030.
24. Tan M., Fang P., Chachiyo T., Xia M., Huang P., Fang Z., et al. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 2008, 382:115-123.
25. Huang P., Farkas T., Marionneau S., Zhong W., Ruvoen-Clouet N., Morrow A.L., et al. Noroviruses bind to human ABO, lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003, 188:19-31.
26. Huang P., Farkas T., Zhong W., Tan M., Thornton S., Morrow A.L., et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005, 79:6714-6722.
27. Tan M., Meller J., Jiang X. C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein. J Virol 2006, 80:7322-7331.
28. Tan M., Xia M., Cao S., Huang P., Farkas T., Meller J., et al. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 2008, 379:324-334.
29. Tan M., Xia M., Chen Y., Bu W., Hegde R.S., Meller J., et al. Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS One 2009, 4:e5058.
30. Tan M., Hegde R.S., Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J Virol 2004, 78:6233-6242.
31. Xia M., Farkas T., Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 2007, 79:74-83.
32. Yang Y., Xia M., Tan M., Huang P., Zhong W., Pang X.L., et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol 2010, 84:9595-9607.
33. LoBue A.D., Lindesmith L., Yount B., Harrington P.R., Thompson J.M., Johnston R.E., et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006, 24:5220-5234.
34. Tan M., Jiang X. Norovirus-host interaction: multi-selections by the human HBGAs. Trends Microbiol 2011, 19:382-388. 10.1016/j.tim.2011.05.007.
35. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
36. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001, 166:481-489.
37. Krikorian D., Panou-Pomonis E., Voitharou C., Sakarellos C., Sakarellos-Daitsiotis M. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates. Bioconjug Chem 2005, 16:812-819.